Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sanofi-Aventis S.A. ADR
(NQ:
SNY
)
48.82
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Sanofi-Aventis S.A. ADR
< Previous
1
2
3
Next >
Is DoubleVerify’s 39% Haircut a Buying Opportunity?
May 15, 2024
Digital advertising verification and measurement solutions provider DoubleVerify Holdings Inc. (NYSE: DV) shares took a 39% plunge on its Q1 2024 earnings
Via
MarketBeat
Topics
Artificial Intelligence
Fraud
Malware
Exposures
Artificial Intelligence
Information Security
Legal
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
May 13, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
May 13, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Sanofi (NASDAQ: SNY) Records 52-Week High Wednesday Morning
April 26, 2023
Via
Investor Brand Network
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
May 13, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
The 16th Annual Global CSR & ESG Summit and Awards 2024: Celebrating Sustainable Leadership and Innovation, 25 April 2024
April 30, 2024
From
Pinnacle Group International
Via
ACN Newswire
Novo Nordisk Arms Wegovy to Be a Triple Threat
April 15, 2024
Novo Nordisk has had success with Ozempic and Wegovy for Type 2 diabetes and obesity, seeks to expand indications to include cardio diseases and neuro disorders
Via
MarketBeat
6 reasons to buy Teva Pharmaceuticals stock sooner than later
February 26, 2024
Investors seeking a long-term and undervalued pharmaceutical play should take a close look at Teva Pharmaceuticals, and here are six reasons why
Via
MarketBeat
Topics
Lawsuit
Exposures
Financial
Legal
Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
January 25, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Time to buy these 3 healthcare companies that raised revenue guidance?
January 16, 2024
The new year brings a clean slate heading into the fourth-quarter earnings season. Check out a few companies that have raised revenue guidance.
Via
MarketBeat
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
November 30, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Pharma is the way to play the re-rise of generic drugs
November 28, 2023
Generic and specialty pharmaceutical company, Teva Pharmaceutical's stock, has underperformed for years, but a potential spinoff may be a catalyst for growth
Via
MarketBeat
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
November 27, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
MarketBeat Week in Review – 11/6 - 11/10
November 11, 2023
Stocks closed the week with a strong rally, but the rally may reverse when investors get the latest information about inflation and retail stocks next week
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Exposures
Artificial Intelligence
Interest Rates
Pfizer and Sanofi shares fall, which one to scoop up?
November 07, 2023
Pharmaceutical stocks aren't having a banner year; notably, two large pharmaceutical companies recently plunged to 52-week lows
Via
MarketBeat
Exposures
COVID-19
Get Ready for Next Generation of Diabetes, Weight-Management Drugs
November 01, 2023
Via
Investor Brand Network
Get Ready for Next Generation of Diabetes, Weight-Management Drugs
November 01, 2023
EQNX::TICKER_START (NASDAQ:LEXX),(NYSE:JNJ),(NYSE:SNY),(NASDAQ:AMGN),(NYSE:NVS) EQNX::TICKER_END
Via
FinancialNewsMedia
Investor patience tested as pharmaceutical stocks take a tumble
November 01, 2023
The healthcare sector faces a selloff as pharmaceutical giants report lackluster earnings; even Amgen's strong results failed to prevent selling in the sector
Via
MarketBeat
Acurx Pharmaceuticals Share Price And Volume Are Surging Ahead Of Phase 2b Trial Data Release ($ACXP)
October 27, 2023
Via
AB Newswire
Topics
Death
Exposures
Death
Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)
October 22, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Sanofi Bridging the Gap between the Homeless and Society via Futsal
October 17, 2023
From
sanofi-aventis Korea
Via
Business Wire
Why the Relapsed/Refractory Acute Myeloid Leukemia Market is Expected to Witness Revolutionary Developments
October 24, 2023
EQNX::TICKER_START (NASDAQ:TCBP),(NYSE:CVM),(NASDAQ:INVO),(NASDAQ:SNY),(NYSE:PFE) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment
October 04, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review
September 26, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Here are 3 AI Drug Discovery Stocks to Put on Your Watchlist
August 01, 2023
Artificial intelligence (AI) has hit the mainstream with fervor. Specifically, generative AI has gone viral with the explosion in ChatGPT users.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Exscientia is the Sniper of the AI Drug Discovery Industry
July 27, 2023
News of a $50 million investment by artificial intelligence (AI) leader Nvidia Co. (Nasdaq: NVDA) into AI-powered drug discovery company Recursion
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Recludix Pharma Enters into a Strategic Collaboration with Sanofi to Advance Novel Oral STAT6 Inhibitor in Multiple Immunological and Inflammatory Indications
July 20, 2023
From
Recludix Pharma, Inc.
Via
GlobeNewswire
DarioHealth is an AI-Powered Digital Therapeutics Play
June 13, 2023
DarioHealth Co. (NASDAQ: DRIO) is an AI-powered digital therapeutics platform and provider that adaptively personalizes monitoring and treatments for chronic
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
May 18, 2023
These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.
Via
MarketBeat
Exposures
Product Safety
Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales
May 05, 2023
Regeneron reported better-than-expected Q1 earnings and revenue, but its Eylea sales fell, losing ground to Roche's newly launched Vabysmo.
Via
MarketBeat
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.